• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

作者信息

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama B P, Ravaud A, Shariat S F, Szabados B, van der Heijden M S, Gillessen S

机构信息

Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK.

Beth Israel Deaconess Medical Centre-IMIM Lab, Harvard Medical School, Boston, USA.

出版信息

Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30.

DOI:10.1016/j.annonc.2021.11.012
PMID:34861372
Abstract
摘要

相似文献

1
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.膀胱癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30.
2
[Innovations in systemic treatment of urothelial carcinoma].[尿路上皮癌全身治疗的创新]
Bull Cancer. 2020 Jun;107(5S):S6-S16. doi: 10.1016/S0007-4551(20)30273-3.
3
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.欧洲肿瘤内科学会（ESMO）晚期尿路上皮癌一线治疗临床实践指南临时更新
Ann Oncol. 2024 Jun;35(6):485-490. doi: 10.1016/j.annonc.2024.03.001. Epub 2024 Mar 13.
4
Evolving systemic management of urothelial cancers.尿路上皮癌的系统治疗进展。
Curr Opin Oncol. 2023 May 1;35(3):186-199. doi: 10.1097/CCO.0000000000000942. Epub 2023 Mar 14.
5
Current Therapy for Metastatic Urothelial Carcinoma.转移性尿路上皮癌的当前治疗方法。
Hematol Oncol Clin North Am. 2021 Jun;35(3):469-493. doi: 10.1016/j.hoc.2021.02.010. Epub 2021 Apr 10.
6
The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.抗体药物偶联物在尿路上皮癌中的应用进展。
Clin Genitourin Cancer. 2021 Jun;19(3):183-193. doi: 10.1016/j.clgc.2020.11.006. Epub 2020 Dec 2.
7
Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.膀胱癌化疗改良的新兴策略：当前知识与未来展望。
J Adv Res. 2022 Jul;39:187-202. doi: 10.1016/j.jare.2021.11.010. Epub 2021 Nov 24.
8
A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.一种治疗膀胱癌的新策略：抗体药物偶联物。
Investig Clin Urol. 2022 Jul;63(4):373-384. doi: 10.4111/icu.20220061. Epub 2022 May 30.
9
An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.尿路上皮癌中抗体药物偶联物的最新进展：最新策略及未来发展方向。
Cancer Chemother Pharmacol. 2022 Sep;90(3):191-205. doi: 10.1007/s00280-022-04459-7. Epub 2022 Aug 11.
10
[Antibody-drug conjugates as new therapeutic agents in uro-oncology].[抗体药物偶联物作为尿路上皮肿瘤学的新型治疗药物]
Urologie. 2023 Jul;62(7):679-684. doi: 10.1007/s00120-023-02118-0. Epub 2023 Jun 9.

引用本文的文献

1
Advances in the immunological microenvironment and immunotherapy of bladder cancer.膀胱癌免疫微环境与免疫治疗的进展
Front Immunol. 2025 Aug 19;16:1609871. doi: 10.3389/fimmu.2025.1609871. eCollection 2025.
2
Rare Case of Large Bowel Obstruction due to Plasmacytoid Urothelial Carcinoma.浆细胞样尿路上皮癌导致大肠梗阻的罕见病例。
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0301. Epub 2025 Aug 26.
3
Urinary bladder cancer needs more attention - recommendations for health care professionals and politicians in the European Union.
膀胱癌需要更多关注——给欧盟医疗保健专业人员和政治家的建议
Nat Rev Urol. 2025 Aug 19. doi: 10.1038/s41585-025-01077-9.
4
Exploring Natural Products to Target Ferroptosis in Urologic Malignancies: Advancements from Molecular Mechanisms to Therapeutic Strategies.探索用于靶向泌尿生殖系统恶性肿瘤中铁死亡的天然产物：从分子机制到治疗策略的进展
Chin J Integr Med. 2025 Aug 13. doi: 10.1007/s11655-025-4140-2.
5
Editorial: Multidisciplinary management of urological malignancies in the era of precision medicine: integration of advances in technology and cancer care.社论：精准医学时代泌尿外科恶性肿瘤的多学科管理：技术进展与癌症治疗的整合
Front Urol. 2025 Jan 8;4:1518410. doi: 10.3389/fruro.2024.1518410. eCollection 2024.
6
Oncological and functional outcomes and complications of robotic intracorporeal Studer orthotopic neobladder: A single-center retrospective study.机器人体内Studer原位新膀胱的肿瘤学和功能结局及并发症：一项单中心回顾性研究。
Bladder (San Franc). 2025 Jan 9;12(1):e21200029. doi: 10.14440/bladder.2024.0025. eCollection 2025.
7
Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma.开放性与微创性肾输尿管切除术治疗局部晚期上尿路尿路上皮癌的肿瘤学结局
World J Urol. 2025 Jul 23;43(1):452. doi: 10.1007/s00345-025-05815-x.
8
The impact of METTL3 on bladder cancer through mA modification: a potential therapeutic target and prognostic biomarker.METTL3通过m⁶A修饰对膀胱癌的影响：一个潜在的治疗靶点和预后生物标志物。
Front Oncol. 2025 Jul 3;15:1622117. doi: 10.3389/fonc.2025.1622117. eCollection 2025.
9
The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.DNA甲基化与去甲基化在膀胱癌中的作用：聚焦治疗策略
Front Oncol. 2025 Jun 26;15:1567242. doi: 10.3389/fonc.2025.1567242. eCollection 2025.
10
Brain metastasis in a patient with metastatic urothelial carcinoma after 7 years of avelumab maintenance therapy: A case report.阿维鲁单抗维持治疗7年后转移性尿路上皮癌患者发生脑转移：一例报告
Urol Case Rep. 2025 Jun 16;61:103109. doi: 10.1016/j.eucr.2025.103109. eCollection 2025 Jul.